Brenner, Ellen
Schörg, Barbara F. http://orcid.org/0000-0001-5163-1556
Ahmetlić, Fatima
Wieder, Thomas
Hilke, Franz Joachim
Simon, Nadine
Schroeder, Christopher
Demidov, German http://orcid.org/0000-0001-9075-4276
Riedel, Tanja
Fehrenbacher, Birgit
Schaller, Martin
Forschner, Andrea
Eigentler, Thomas
Niessner, Heike
Sinnberg, Tobias http://orcid.org/0000-0003-3922-3327
Böhm, Katharina S.
Hömberg, Nadine
Braumüller, Heidi
Dauch, Daniel
Zwirner, Stefan
Zender, Lars
Sonanini, Dominik
Geishauser, Albert
Bauer, Jürgen
Eichner, Martin
Jarick, Katja J. http://orcid.org/0000-0001-5162-7266
Beilhack, Andreas
Biskup, Saskia
Döcker, Dennis
Schadendorf, Dirk http://orcid.org/0000-0003-3524-7858
Quintanilla-Martinez, Leticia
Pichler, Bernd J.
Kneilling, Manfred
Mocikat, Ralph
Röcken, Martin
Article History
Received: 26 November 2018
Accepted: 7 February 2020
First Online: 12 March 2020
Competing interests
: M.R., E.B. and T.W. are inventors of an European pending patent Number 13 826 993.1: “Use of active substance combinations for tumour senescence” and an United States patent Number US 10,046,029 B2: “Method of inducing senescence in tumour cells by administrating TNF-A in combination with IFN-A of IFN-Y”. As chairperson M.R. has to sign all contracts of the department. M.R. receives grants for research projects or travel support and has the indicated shares. The authors B.P and M.K have research contracts with Imaging modality suppliers, and are members of the “ImmuneImage” consortium within the Horizon2020 IMI programme of the European Union. F.J.H reports institutional research support from Novartis. C.S. reports research support from Illumina and institutional research support from Novartis. All remaining authors declare no competing interests.